These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28853901)

  • 1. Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.
    Saeui CT; Liu L; Urias E; Morrissette-McAlmon J; Bhattacharya R; Yarema KJ
    Mol Pharm; 2018 Mar; 15(3):705-720. PubMed ID: 28853901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxicity and MUC1 suppression.
    Aich U; Campbell CT; Elmouelhi N; Weier CA; Sampathkumar SG; Choi SS; Yarema KJ
    ACS Chem Biol; 2008 Apr; 3(4):230-40. PubMed ID: 18338853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery.
    Elmouelhi N; Aich U; Paruchuri VD; Meledeo MA; Campbell CT; Wang JJ; Srinivas R; Khanna HS; Yarema KJ
    J Med Chem; 2009 Apr; 52(8):2515-30. PubMed ID: 19326913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular and intracellular esterase processing of SCFA-hexosamine analogs: implications for metabolic glycoengineering and drug delivery.
    Mathew MP; Tan E; Shah S; Bhattacharya R; Adam Meledeo M; Huang J; Espinoza FA; Yarema KJ
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6929-33. PubMed ID: 23041156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
    Sevrioukova IF; Poulos TL
    Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoengineering of Esterase Activity through Metabolic Flux-Based Modulation of Sialic Acid.
    Mathew MP; Tan E; Labonte JW; Shah S; Saeui CT; Liu L; Bhattacharya R; Bovonratwet P; Gray JJ; Yarema KJ
    Chembiochem; 2017 Jul; 18(13):1204-1215. PubMed ID: 28218815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations.
    Urgaonkar S; Nosol K; Said AM; Nasief NN; Bu Y; Locher KP; Lau JYN; Smolinski MP
    J Med Chem; 2022 Jan; 65(1):191-216. PubMed ID: 34928144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
    Mandal M; Mitra K; Grotz D; Lin X; Palamanda J; Kumari P; Buevich A; Caldwell JP; Chen X; Cox K; Favreau L; Hyde L; Kennedy ME; Kuvelkar R; Liu X; Mazzola RD; Parker E; Rindgen D; Sherer E; Wang H; Zhu Z; Stamford AW; Cumming JN
    J Med Chem; 2018 Dec; 61(23):10700-10708. PubMed ID: 30388368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-chain fatty acids oppositely altered expressions and functions of intestinal cytochrome P4503A and P-glycoprotein and affected pharmacokinetics of verapamil following oral administration to rats.
    Zhang J; Xie Q; Kong W; Wang Z; Wang S; Zhao K; Chen Y; Liu X; Liu L
    J Pharm Pharmacol; 2020 Mar; 72(3):448-460. PubMed ID: 31863502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors.
    Said AM; Mansour YE; Soliman RR; Islam R; Fatahala SS
    Eur J Med Chem; 2024 Jul; 273():116492. PubMed ID: 38762918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
    Samuels ER; Sevrioukova IF
    Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.
    Samuels ER; Sevrioukova I
    Biochemistry; 2019 Apr; 58(15):2077-2087. PubMed ID: 30912932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Microbial Short-Chain Fatty Acids on CYP3A4-Mediated Metabolic Activation of Human Pluripotent Stem Cell-Derived Liver Organoids.
    Mun SJ; Lee J; Chung KS; Son MY; Son MJ
    Cells; 2021 Jan; 10(1):. PubMed ID: 33440728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
    Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
    Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment.
    Quignot N; Wiecek W; Amzal B; Dorne JL
    Arch Toxicol; 2019 Jan; 93(1):107-119. PubMed ID: 30298208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sophora flavescens (Ku-Shen) as a booster for antiretroviral therapy through cytochrome P450 3A4 inhibition.
    Lin ZX; Che CT; Lee SS; Chan RC; Ip PS; Yang JM
    Hong Kong Med J; 2015 Dec; 21 Suppl 7():S18-21. PubMed ID: 26908268
    [No Abstract]   [Full Text] [Related]  

  • 17. Acetaminophen analog N-acetyl-m-aminophenol, but not its reactive metabolite, N-acetyl-p-benzoquinone imine induces CYP3A activity via inhibition of protein degradation.
    Santoh M; Sanoh S; Ohtsuki Y; Ejiri Y; Kotake Y; Ohta S
    Biochem Biophys Res Commun; 2017 May; 486(3):639-644. PubMed ID: 28341123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor.
    Vaz RJ; Li Y; Munson M; Elliot M; Thurairatnam S
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3046-3049. PubMed ID: 30115511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative.
    Alrushaid S; Zhao Y; Sayre CL; Maayah ZH; Forrest ML; Senadheera SN; Chaboyer K; Anderson HD; El-Kadi AOS; Davies NM
    Drug Deliv Transl Res; 2017 Aug; 7(4):582-597. PubMed ID: 28462502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity.
    Tu M; Li L; Lei H; Ma Z; Chen Z; Sun S; Xu S; Zhou H; Zeng S; Jiang H
    Toxicology; 2014 Aug; 322():34-42. PubMed ID: 24799337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.